Livforsakringsbolaget Skandia Omsesidigt Invests $79,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 400 shares of the medical research company’s stock, valued at approximately $79,000.

Several other institutional investors have also recently added to or reduced their stakes in CRL. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares during the period. Headlands Technologies LLC purchased a new stake in Charles River Laboratories International in the 1st quarter valued at $41,000. Whittier Trust Co. of Nevada Inc. raised its position in Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after buying an additional 193 shares during the last quarter. Concord Wealth Partners raised its position in Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after buying an additional 203 shares during the last quarter. Finally, Sunbelt Securities Inc. raised its position in Charles River Laboratories International by 1,072.7% in the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after buying an additional 236 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Barclays lowered their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Robert W. Baird reduced their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Finally, TD Cowen reduced their price objective on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $212.23.

Charles River Laboratories International Stock Up 0.4 %

CRL stock opened at $193.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. The company has a market capitalization of $9.98 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00. The stock has a fifty day moving average of $197.44 and a 200-day moving average of $214.81.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).